New drug duo aims to wipe out breast cancer before surgery
NCT ID NCT07466303
Summary
This study is testing whether a combination of two newer drugs, serplulimab and SHR-A1811, can effectively shrink tumors in patients with early-stage triple-negative breast cancer before they have surgery. The goal is to see if this non-chemotherapy approach can completely eliminate the cancer in the breast and lymph nodes, potentially leading to better long-term outcomes. About 84 eligible patients will receive the drug combination for about 18 weeks prior to their planned operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of the Air Force Medical University
Xi'an, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.